To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: ECCMID: Once Daily Moxifloxacin As Effective As Amoxicillin/Clavulanate In Treating Acute Sinusitis URL: http://www.pslgroup.com/dg/1F704A.htm Doctor's Guide April 4, 2001
By Pamela A. Hunter Special to DG News ISTANBUL, TURKEY -- April 4, 2001 -- Moxifloxacin is a new fluoroquinolone with increased activity against Gram-positive cocci compared with ciprofloxacin. In addition, the compound is well absorbed orally and has good bioavailability, allowing it to be dosed only once a day. Its spectrum of activity covers most of the common pathogens found in upper and lower respiratory tract infections, and no cross resistance is seen between moxifloxacin and macrolides or beta-lactams. Sinusitis is an infection that affects a substantial proportion of the population, at least 14 percent in the USA, and has a considerable impact on health care facilities. At the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Istanbul, Dr. J. Arrieta and colleagues from Toriello Guerro, Mexico, reported on a study in which they had compared once-daily dosing of moxifloxacin at 400 mg for seven days with 625 mg of amoxicillin/clavulanate dosed three times daily for 10 days in the treatment of acute sinusitis. Patients who had had signs and symptoms of sinusitis for at least seven days were recruited. The symptoms included facial pain at any sinus site, purulent nasal discharge, cough, fever, headache, or nasal congestion. Two-hundred and twenty-seven patients received moxifloxacin and 233 patients received amoxicillin/clavulanate. No differences were evident in the demographic or baseline characteristics of the patients in the two groups. Clinical resolution of symptoms at seven to 14 days after the end of therapy was seen in 93.4 percent of the moxifloxacin patients and 93.6 percent of the amoxicillin/clavulanate patients indicating equivalence of treatments. The bacteriological success rates were also equivalent. The safety and tolerance of both treatments was similar overall, although there were slightly more drug-related adverse events with moxifloxacin (32.2 percent versus 29.7 percent), but the same number of serious adverse events. The authors concluded that moxifloxacin was equivalent in treatment to amoxicillin/clavulanate for acute sinusitis, but has advantages for the patient since it only needs to be dosed once a day and for a shorter period. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.